Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Cytori Therapeutics (CYTX), Post-Hoc APOLLO Study

Adipose-Derived Regenerative Cell (ADRC) therapy associated with reduction in arrhythmia in acute heart attack patients.

CYTX presented data reported at the 6th International Conference on Cell Therapy for Cardiovascular Disease demonstrating a statistically significant reduction in ventricular tachyarrhythmia following adipose-derived regenerative cell (ADRC) therapy in patients with acute heart attack.

  • The findings were presented by Henricus J. Duckers, M.D., Ph.D., Interventional Cardiologist, Head of Molecular Cardiology, Thoraxcentre, Erasmus University Hospital, Rotterdam, the Netherlands.

In Dr. Duckers’ presentation, ADRC therapy was associated with a significantly lower incidence of ventricular tachyarrhythmia.

  • A total of 3 episodes of ventricular tachyarrhythmia were reported in the treated group as compared to 10 in the control group (p=0.018);
  • On a per patient basis, the treated group experienced a mean of 0.3 episodes of ventricular tachyarrhythmia as compared to 2.5 in the control group (p=0.048);
  • The analysis of Holter recordings also indicated lower incidence of premature ventricular contractions (PVC, a single abnormal beat) in patients treated with ADRCs. In ADRC-treated patients, 5 PVCs per patient, per day, were reported whereas in placebo-treated patients, the number of PVCs reported per patient, per day, was 72 (p=0.014);
  • Forty-eight hour Holter recordings were obtained weekly for the first month after discharge followed by 24-hour recordings at 2, 3, 4 and 6 months post-procedure. All Holter recordings were assessed by an independent, blinded Holter core laboratory. Post-hoc data analyses of Holter data were conducted independently by Thoraxcentre.

Although … not the primary study endpoint, the observed reduction in arrhythmias supports … the safety of ADRCs in the treatment of patients with an acute heart attack.